Glivec 400mg tablet

Blood cancer (Chronic myeloid leukaemia)
Gastrointestinal stromal tumour
Treatment of Cancer

The human body reacts differently to the Glivec 400mg tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of the Glivec 400mg tablet are mentioned below: Diarrhea
Vomiting
Nausea
Loss of appetite
Dizziness
Extreme fatigue 
Blurred vision
Irregular heart rate
Chest pain
Muscle cramps
Pink eye  
Redness and rashes, Swelling of joints
Trouble sleeping
Hair loss
Shortness of breath
Yellowing of eyes and skin
Pink mucous in the cough
Sudden weight loss or weight gain

Take the dose of the Glivec 400mg tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Glivec 400mg tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.

Glivec 400mg tablet stops the growth and spread of cancer by targeting the specific protein that helps the tumour cells to grow. It is an anticancer medication. Glivec 400mg tablet is an anti-cancer medication that inhibits the proliferation of BCR-ABL tyrosine kinase, a protein enzyme. This enzyme helps cancer cells multiply and is responsible for the abnormal proliferation of cancer cells. Glivec 400mg tablet also induces apoptosis (programmed cell death) in BCR-ABL positive cells (cancer cells) and shows antineoplastic properties, stopping or slowing the spread of cancer cells.

​It is advisable to avoid missing any doses. In case you miss a dose of Glivec tablets consult your doctor immediately.​

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P. (2024). Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 44(2):158-62.

Zhu J, Yang Y, Zhou L, Jiang M, Hou M. (2024). A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome. BMC Cancer. 10:199.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. (2025). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279(5350):577–580. 

Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. (2024). KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 160(5):1567–1572. 

Mudan SS, Conlon KC, Woodruff JM, Lewis JJ, Brennan MF. (2025). Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection. Cancer. 88(1):66–74. 

Demetri GD, von Mehren M, Blanke CD, Abbeele AD Van den, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. (2024). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 347(7):472–480.